Literature DB >> 24855479

Provincial and temporal variation in macrolide and lincosamide antimicrobial use by outpatients in Canada, 1995 to 2010.

Shiona K Glass-Kaastra1, Rita Finley1, Jim Hutchinson2, David M Patrick3, Karl Weiss4, John Conly5.   

Abstract

INTRODUCTION: Because antimicrobial use is commonly associated with the development of antimicrobial resistance, monitoring the volume and patterns of use of these agents is very important.
OBJECTIVE: To assess the use of macrolide and lincosamide (ML) antimicrobials within Canadian provinces over time, and to compare use rates with those reported by European countries.
METHODS: ANTIMICROBIAL PRESCRIBING DATA WERE USED TO DEVELOP TWO YEARLY METRICS: prescriptions per 1000 inhabitant-days (PrIDs) and the mean defined daily doses (DDDs) per prescription, which were then used to build linear mixed models to assess differences among provinces over time.
RESULTS: After accounting for repeated measures over time, prescribing rates (PrIDs) varied significantly according to province and year (P<0.001). However, little change occurred within each province over the time frame studied; from 1995 to 2010, each province had a PrID change <0.01. Quebec and British Columbia had significantly lower prescribing rates than all other provinces. No overall secular trend was apparent. In contrast, the DDDs per prescription did not vary significantly according to province, but showed a significant year-to-year increase. DISCUSSION: ML prescribing varied among provinces in Canada between 1995 and 2010, but remained relatively stable within each province. The average DDDs per ML prescription did not vary according to province, but increased linearly over time. These increases are likely to indicate that fewer prescriptions are being written for children over time, a practice supported by good antimicrobial stewardship principles.

Entities:  

Keywords:  Antimicrobial use; Macrolides; Prescribing practices; Provincial variation; Surveillance

Year:  2014        PMID: 24855479      PMCID: PMC4028665          DOI: 10.1155/2014/904053

Source DB:  PubMed          Journal:  Can J Infect Dis Med Microbiol        ISSN: 1712-9532            Impact factor:   2.471


  3 in total

1.  Longitudinal surveillance of outpatient β-lactam antimicrobial use in Canada, 1995 to 2010.

Authors:  Shiona K Glass-Kaastra; Rita Finley; Jim Hutchinson; David M Patrick; Karl Weiss; John Conly
Journal:  Can J Infect Dis Med Microbiol       Date:  2014-03       Impact factor: 2.471

2.  European Surveillance of Antimicrobial Consumption (ESAC): outpatient antibiotic use in Europe (1997-2009).

Authors:  Niels Adriaenssens; Samuel Coenen; Ann Versporten; Arno Muller; Girma Minalu; Christel Faes; Vanessa Vankerckhoven; Marc Aerts; Niel Hens; Geert Molenberghs; Herman Goossens
Journal:  J Antimicrob Chemother       Date:  2011-12       Impact factor: 5.790

3.  European Surveillance of Antimicrobial Consumption (ESAC): outpatient macrolide, lincosamide and streptogramin (MLS) use in Europe (1997-2009).

Authors:  Niels Adriaenssens; Samuel Coenen; Ann Versporten; Arno Muller; Girma Minalu; Christel Faes; Vanessa Vankerckhoven; Marc Aerts; Niel Hens; Geert Molenberghs; Herman Goossens
Journal:  J Antimicrob Chemother       Date:  2011-12       Impact factor: 5.790

  3 in total
  1 in total

1.  Emergence of Serotype IV Group B Streptococcus Adult Invasive Disease in Manitoba and Saskatchewan, Canada, Is Driven by Clonal Sequence Type 459 Strains.

Authors:  Sarah Teatero; Taryn B T Athey; Paul Van Caeseele; Greg Horsman; David C Alexander; Roberto G Melano; Aimin Li; Anthony R Flores; Samuel A Shelburne; Allison McGeer; Walter Demczuk; Irene Martin; Nahuel Fittipaldi
Journal:  J Clin Microbiol       Date:  2015-07-01       Impact factor: 5.948

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.